Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206206 · ClinicalTrials.gov registry record · NA
Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart
A NA study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- NA
- Development phase
- 235
- Enrollment target
NCT00206206: Clinical Trial NA study, sponsored by Atlantic Health System.
NCT00206206 is a NA study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 235 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206206, a NA study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 235 participants
- Enrollment target
Study Summary
In response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the MMH ICU developed a protocol utilizing regular intravenous insulin. This protocol was initiated in 2002. Monitoring of the data collected revealed effective glycemic control when this protocol was used. However, limited utilization has led to overall ineffective glycemic control in this ICU. The poor utilization is largely due to a general reluctance of physicians to start their patients on an intravenous insulin infusion. As contributing to this poor compliance is the "open" nature of the ICU. The MMH ICU is an "open" ICU, meaning that many physicians across multiple subspecialties admit to this unit. Approaches to controlling hyperglycemia vary greatly, depending largely upon the treating physician. In an attempt to improve overall glycemic control in this "open" ICU, the Subcutaneaous Insulin Aspart Hyperglycemia Protocol (SIAP) was developed which incorporates a subcutaneous insulin aspart regimen that triggers the use of a regular insulin infusion protocol when the SIAP is not adequately controlling the patient's blood glucose. This study aims to evaluate 1) the effect the SIAP on overall glycemic control in the ICU, 2) the effectiveness that the SIAP has on controlling blood glucose as compared with past practices using regular insulin, and 3) the effect the SIAP has on patient complications and outcomes in the MMH ICU.
Interventions
- PROCEDURE Hyperglycemia Protocol Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2005-07 |
| Phase | NA |
Why NCT00206206 stopped before completion
NCT00206206 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Hyperglycemia Protocol Procedure is the first listed.
NCT00206206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206206 about?
NCT00206206 is a clinical study titled "Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart". In response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the MMH ICU developed a protocol utilizing regular intravenous insulin. This protocol was initiated in 2002. Monitoring of the data collected revealed effective glycemic control when this protocol...
What is the current status of trial NCT00206206?
This trial is currently terminated. It is a NA study. The enrollment target is 235 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00206206?
The interventions under investigation include: Hyperglycemia Protocol Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00206206?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206206's enrollment target sits among peer trials
235 461st of 2000 higher than 1,539 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia